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Abstract
In the year 2001 a collection of yeast strains will be completed that are deleted in the 6000
open reading frames selected as putative genes by the initial bioinformatic analysis of the
Saccharomyces cerevisiae genome. The collection was produced by the transatlantic yeast
gene deletion project, a collaboration involving researchers in the USA, Canada and
Europe. The European effort was part of EUROFAN (European Functional Analysis
Network) where some of the strains could feed into various functional analysis nodes
dealing with speciﬁc areas of cell biology. With approximately 40% of human genes
involved in heritable disease having a homologue in yeast and with the use of yeast in
various drug discovery strategies, not least due to the dramatic increase in fungal
infections, these strains will be valuable in trans-genomic studies and in specialised interest
studies in individual laboratories. A detailed analysis of the project by the consortium is in
preparation, here we discuss the yeast strains, reported ﬁndings and approaches to using
this resource. Copyright # 2001 John Wiley & Sons, Ltd.
Introduction
The budding yeast Saccharomyces cerevisiae serves
as a central model eukaryotic organism in biologi-
cal research and is important in biotechnology.
Completion of the S. cerevisiae sequencing project,
the ﬁrst for a eukaryotic genome, indicated the
presence of approximately 6000 putative open
reading frames (ORFs) that are likely to encode
protein products in the yeast cell (Goffeau et al.,
1996). Initial analysis of the sequence revealed the
existence of approximately 6275 ORFs that theore-
tically could encode proteins greater than 99 amino
acids and attempts were made to classify yeast
proteins according to their predicted function.
Initially it was estimated that the yeast cell devotes
11% of its proteome to metabolism; 3% to energy
production and storage; 3% to DNA replication,
repair and recombination; 7% to transcription and
6% to translation. Some 430 proteins were predicted
to be involved in protein targeting or intracellular
trafﬁcking, 250 as structural proteins, 200 as tran-
scription factors and 250 involved in transport.
However, approximately 50% of ORFs contained
within the yeast genome were of no known function.
A long-standing approach for the determination
of gene function has been through the phenotypic
analysis of mutants missing the particular gene of
interest, but many genes were not identiﬁed by
classical genetic approaches. The speciﬁc deletion of
a yeast gene in a directed approach involves
generation of a deletion cassette by the polymerase
chain reaction (PCR) (Wach et al., 1994) and takes
advantage of the high level of homologous recom-
bination in yeast. Short-ﬂanking homology of only
40 base pairs allows a precise replacement of an
open-reading frame with a selectable marker. Con-
ceptually, as well as practically it became possible to
envisage deleting each of the ORFs identiﬁed by the
yeast genome sequencing project and this was the
strategy adopted by a consortium of yeast labora-
tories based both in Europe and North America.
Within the deletion cassette produced for each ORF
modiﬁcations were introduced that can mark the
speciﬁc gene with a unique identiﬁer (or molecular
barcode) so that serial analysis of phenotypes of
mutant strains becomes easier.
European functional analysis network
(EUROFAN)
The ﬁrst EUROFAN programme established an
approach whereby the function of a particular gene
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city, by moving it from one level of analysis to
another. This hierarchical scheme was divided
between different participating groups, or Nodes,
that concentrated on a particular aspect of cell
structure or metabolism (Table 1). This organisa-
tion was efﬁcient since communication between
groups meant that not all genes had to have
every analysis performed on them. It is pertinent
that this systematic functional analysis was not
intended to replace ‘‘normal’’ biological research,
but it was a stated aim that analysis of each
novel gene could be taken to a particular level
whereby an interested laboratory could incorpo-
rate it into its own research programme.
The ﬁrst level of analysis was the so-called B0
phase, where deletion strains and replacement
cassettes were generated for ORFs in the S.
cerevisiae genome. Under EUROFAN’s ﬁrst pro-
gramme a thousand open-reading frames were
targeted for deletion using a similar strategy to
the later transatlantic project, but where the
molecular barcodes were absent. These were
undertaken in Europe through the distribution of
sets of six genes (so-called ‘six packs’) to various
laboratories.
Transatlantic yeast gene deletion project
In the second EUROFAN programme, the B0 node
was part of the transatlantic consortium under-
taking the task of generating a genome-wide set
of gene deletion strains beginning in 1998. The
participants in the project are indicated in Table 2.
A total of 6138 ORFs were subjected to targeted
deletions in a diploid reference strain, BY4743
(Table 3). ORFs were organised into groups of 96
starting from the left arm of a chromosome, so
that participating laboratories were assigned sets
of primers distributed in a multi-well format to
generate PCR products for targeted deletion, with
further sets of conﬁrmation primers also in the
same format. A major challenge to the success of
the project was the design and synthesis of primers
targeted against such a large number of ORFs. All
the primers used in this work were designed by
computer algorithms and synthesis co-ordinated at
the Stanford Resource Centre. Primer sequences
and ORF locations were chosen from the Stanford
Genome Database (http://genome.www.stanford.edu/
Saccharomyces/). Although y10% of the predicted
ORFs in S. cerevisiae overlap one another, the
positions of the deletions were not adjusted and no
Table 1. Hierarchy of Eurofan consortia. Level A: service or material resources for the whole of Eurofan.
Level B: provided the ﬁrst level of searching for function and permitted approximate assignments that allowed
individual genes to be passed to the next more speciﬁc level. The functional analysis nodes were divided into
three clusters, F1, F2 and F3
Eurofan Resource Consortia
A1 Central coordination
A2 Informatics
A3 Industrial Liason/Yeast Iindustrial Platform (YIP)
A4 Genetic Archive & Stock centre
Basic Fundemental Analyses
B0 High throughput generation of deletants
B1 Qualitative phenotypic analysis
B2 Transcript analysis
B3 Essential genes
B4 Integrative approaches to to functional analysis
Function Analysis Nodes
F1 Nuclear dynamics N1 Genome Plasticity/Nuclear Structure/Meiosis
N2 Chromosome Structure/Architecture & Biology
F2 Metabolic interactions N3 Transport
N4 Organelles
F3 Cell Organisation & Development N5 Secretion & Protein Trafﬁcking
N6 Cell Architecture
N7 Cell Walls & Morphogenesis
N8 Development
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genes in which a previous deletion had been
constructed, or genes with a well deﬁned function.
Genes represented multiple times in the genome
were not deleted as their targeted disruption was
considered to be problematic.
For the generation and conﬁrmation of each
deletion cassette, eight different primers were
synthesised for each ORF. Four oligonucleotides
(two 74mers and two 45mers) were used in the
synthesis of the deletion module used in the yeast
transformation. The strategy is given in Figure 1.
Speciﬁcally, short regions of yeast DNA sequence
identical to those found upstream and downstream
of a targeted gene are placed at each end of the
antibiotic resistance cassette, KanMX4 (U1, D1)
though PCR. In addition, two molecular barcodes
(UPTAG and DOWNTAG) are introduced into the
deletion strain, a 20 bp tag priming site and 18 bases
of sequence complementary to the ORF. The deletion
cassettes were designed to remove the entire coding
sequence for a given ORF, but to leave the start and
stop codon intact. These 74mers were used to amplify
the heterologous KanMX4 module, which contains a
constitutive efﬁcient promoter from a related yeast
strain Ashbya gosspii fused to the kanamycin resis-
tance gene nptI. A second round of PCR using
primers with 45 bases of homology to the region
upstream and downstream of a speciﬁc targeted ORF
further improved targeting. Yeast transformations
with the PCR product allowed for speciﬁc replace-
ment of the targeted gene and gene- deleted strains
were selected for by growth on complete media
containing the antibiotic Geneticin.
To verify correct homologous recombination of
the deletion cassette with the yeast genome, genomic
DNA was isolated from the Geneticin resistant
colonies and used as template in PCR reactions
using two primers common to the KanMX4 module:
Kan B: 5k-CTGCAGCGAGGAGCCGTAAT-3k
Kan C: 5k-TGATTTTGATGACGAGCGTAAT-3k
Four further primers were used to conﬁrm the
correct integration of the deletion module into the
yeast genome (Figure 2), A, B, C, and D. Primers A
and D were from regions up to 400 bases upstream
and downstream of the start and stop codons
respectively. Primers B and C were from within
the ORF. For veriﬁcation, both the A-KanB and
the D-KanC PCR reactions were required to give
the correct size product when analysed by agarose
gel electrophoresis. If one of the A-Kan B or
D-KanC reactions failed to yield a correctly sized
product the identiﬁcation of the correctly sized A-D
product sufﬁced. In addition, haploid deletion
strains were tested for the disappearance of the
wild type AB and CD products.
For approximately 5000 ORF’s the ﬁrst transfor-
mation gave the correct heterozygous deletions as
conﬁrmed by analytical PCR. The remaining ORF’s
have been subject to the same PCR approach using
either the original primer sets or using newly designed
primers. To date 5935 heterozygous strains are now
available as successfully targeted deletions. Of the
remaining ‘difﬁcult’ ORF’s, sequence error, aberrant
conﬁrmation PCR analysis or unknown factors may
account for their not being generated to date.
For each ORF deletion strain viable in a haploid
Table 2. Members of the Transatlantic Yeast Gene
Deletion Consortium
Consortium Member
U.S./Canada
Acacia Biosciences, Richmond, California
Jef Boeke, Johns Hopkins University
Howard Bussey, McGill University
Ron Davis, Stanford University
Mark Johnston, Washington University at St. Louis
Jasper Rine, University of California at Berkeley
Rosetta Inpharmatics, Kirkland, Washington
Jeffery Strathern/David Garﬁnkel, Frederick Cancer Research and
Development Center
Michael Snyder, Yale University
EUROFAN:
Bruno Andre, University Libre de Bruxelles
Francoise Foury, Universite Catholique de Louvain
Johannes Hegemann, Justus-Liebig-Universitaet Giessen
Steven Kelly, University of Wales Aberystwyth
Peter Philippsen, Biozentrum, Basel
Bart Scherens/ F. Messenguy, Institut de Recherches du CERIA
Jose Revuelta, Universidad de Salamanca
Giorgio Valle, University of Padova
Guido Volckaert, Katholieke Universiteit Leuven
Table 3. Four yeast strains employed in the trans-
atlantic yeast gene deletion project
Yeast Strains
BY4741 MATa ura3D, leu2D, his3D, met15 D, LYS2
BY4742 MATa ura3D, leu2, his3D, MET15, lys2D
BY4743 MATa/a ura3D/ura3 D, leu2 D/leu2D,
his3D/his3D, met15D/MET15, LYS2/lys2D
BY4743HO Homozygous diploid gene deletion strain
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type, were also generated mainly by tetrad dissec-
tion of independent heterozygous deletions in
BY4743 and to a lesser extent by direct trans-
formation of haploid strains (Table 2). Four strain
types were generated when possible; a diploid
heterozygous deletion strain, haploid deletion
strains with either mating type corresponding to
the genotypes of strains BY4171 and BY4172 and a
diploid homozygous deletion strain generated where
possible by mating the corresponding two haploid
strains from independent deletion events.
Strains obtained in the project were examined for
budding patterns, the ability to sporulate, the
inability to mate and for slow growth, besides the
test for their essential nature as reﬂected by tetrad
analysis. Electronic records were kept for every
strain constructed. MATa haploid strains were
given record numbers of less than 10 000, MATa
haploid strains were given record numbers between
10 000 and 20 000, the heterozygous diploid,
between 20 000 and 30 000 and the homozygous
diploid greater than 30 000. Each record is shown
to consist of primer sequence information, the
Figure 1. PCR strategy for targeted deletion of yeast ORFs. A) First round PCR attaches UPTAG and DOWNTAG
sequences. B) Second round PCR extends the sequence to include 45bp homologous to gene to be targeted. C) Following
transformation the kanR module with sequence tags recombines at chromosomal locus of targeted gene
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performed and notes about the phenotype. Data for
all the completed strains can be found at http://www-
sequence.stanford.edu/group/deletion/index.html. All
the generated strains can be obtained from Research
Genetics (Huntsville, AL, USA; http://www.resgen.
com) or EUROSCARF (Frankfurt, Germany; http://
www.uni-frankfurt.de/fb15/mikro/euroscarf/). They are
also available from the American Type Culture
Collection. As an additional task the members of
B0 in EUROFAN II also cloned all the gene
deletion cassettes for their assigned ORFs, which
allows their use in other strains of yeast.
The value and application of a genome
set of gene deletants
With the availability of a set of deletants covering
almost all the predicted open reading frames of
yeast, new opportunities are arising concerning
both fundamental and applied studies in compara-
tive and functional genomics. Some deletants may
be in open-reading frames that are not genes, some
real genes are not currently represented due to the
criteria used in selecting ORFs for deletion and a
limited number were in open reading frames that
were speciﬁcally excluded. A re-evaluation of the
initial annotation of yeast ORFs has appeared
recently, assigning some as spurious (368) and
others as very hypothetical (192) [14]. Thus some
of the deletions are probably not in real genes, but
may have phenotypes if expression of a real gene is
altered. The number of new putative genes detected
(three) will be easily managed in a further set of
gene deletions. Some initial methodology developed
during EUROFAN has been applied to gene
deletions produced in the EUROFAN I Programme
and in the subsequent Transatlantic Yeast Gene
Deletion Consortium where the EU partners
were within EUROFAN II. Unfortunately, while
EUROFAN enabled European laboratories to
contribute to the generation of the genome-
wide set of deletion strains with the US and
Canadian partners, EUROFAN ended at the time
the strains became available for genome-wide
studies. Consequently the techniques and networks
established could not proceed to extensive genome-
wide studies under the same umbrella, but never-
theless the strains can now be used for genomic
studies in the different areas of interest. The
detailed report of the genome-wide gene deletion
study is currently being prepared for publication
and our discussion is consequently restricted to the
implications of the work and how various studies
have indicated the way ahead using sets of gene
deletion strains comprising a part of the total.
Lethals/non-lethal deletants and other
phenotypes
The early stages of the project produced some of
the most readily obtained deletants and allowed an
Figure 2. PCR strategy to conﬁrm gene deletion. 1) Primers A and D when used with primers B and C respectively were
designed to give PCR products in the range of 300–1000 bases. 2) Primers A and D used with primers KanB and KanC
respectively conﬁrmed successful targeted deletion event
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reading frames [13]. Of these the most obvious
interest lay in the proportion of lethal genes that
represented 17% of the total investigated and which
were distributed widely. Phenotypes were also
studied and here the barcode system, identifying
each deletant, could be used to estimate the relative
growth of each of 558 viable homozygous deletion
strains by hybridisation signal. In this way results
were taken and found to tally with expectation.
Mutants deleted in genes needed for growth on
minimal medium were observed to show reduced
growth. The availability of the barcoded deletion
strains allowed integrated studies with transcrip-
tome analysis. Interestingly, little up-regulation of
genes needed for growth on minimal medium was
observed, indicating the value of the possibility of
experiments with deletants as a complementary
technique to transcriptome studies in pinpointing
function. Among all the strains, about 40% showed
growth defects.
Further reports have been made into sets of dele-
tants within the project. For instance, Nierdenthal
et al., [10] found that among 265 genes on chromo-
some VIII, 18% of deletants showed a growth
phenotype and 18% resulted in lethality with growth
on complete medium. They went on to examine
other genetic features, while Lucau-Danila et al., [8]
attempted deletion of 480 genes (ﬁve sets of 96 genes)
across chromosomes III, IV, VII, XII, XIV and XV,
obtaining 456 heterozygotes and 385 homozygotes. In
this study twenty-ﬁve new lethal deletions and thirty
causing slow growth were identiﬁed.
The approach adopted in EUROFAN involved
the development of studies within special interest
nodes. For instance, approaches to lipid meta-
bolism [1] or cell wall synthesis [2] were undertaken.
Reports on the ﬁndings of all the function nodes are
available at: http://www.mips.biochem.mpg.de/.
Identifying and classifying genes involved in cell
wall formation was undertaken with a set of
deletants produced in EUROFAN I [2], strains
without the barcode approach incorporated into the
genome-wide deletions undertaken later. In this
study 620 strains carrying non-essential gene dele-
tions were screened using selections designed to
allow detection of cell wall related phenotypes and
145 showed a phenotype. Extrapolation of their
results suggests that almost 1200 yeast genes may
cause changes in cell wall production. The screening
involved altered sensitivity of strains to calcoﬂuor
white, SDS and sonication or else detection of
different morphology. Similar simple phenotypic
changes detectable by replica plating were favoured
in other nodes, such as the lipid node. There,
altered sensitivity to osmotic stress or membrane
interacting agents such as the antifungal drug
amphotericin B were used [1]. Similar approaches
for sensitivity to DNA damage were also used. The
opportunity to apply these techniques in full
genomic studies is now feasible.
Antifungal and inhibitor mode of action
– haploinsufﬁciency
Almost twenty years ago, the idea of using
increased gene copy number to identify the mode
of action of inhibitors was demonstrated [11]. In
that approach the multi-copy episomal vectors of
yeast allow individual transformants containing a
plasmid expressing the target to be selected from a
library of transformants as a resistant cell line. In
the strains generated in the deletion project a new
technique was developed and evaluated for reveal-
ing haploinsufﬁciency of drug sensitivity in hetero-
zygous diploid strains [3]. This was based on the
increased sensitivity observed for heterozygotes
carrying a deletion of the gene encoding the target
protein of a chemical inhibitor when compared to
strains carrying two wild-type alleles. The increased
sensitivity of that strain identiﬁes the gene product as
the target of the inhibitor and can be detected rapidly
using the unique barcode in hybridisation studies.
The proof of principle was established in detail for
tunicamycin, an inhibitor of glycosylation, using a
pool of 233 heterozygous gene deletion strains.
Genome wide studies must now follow these
preliminary ﬁndings and will reveal full detail on
the modes of action of bioactive compounds.
Further studies on the gene deletion strains have
integrated the transcriptome approach. Despite the
widespread aneuploidy that has been detected in up
to 8% of the deletion strains [5,6] useful information
has and will be gained. In examining the transcrip-
tome response to numerous bioactive inhibitors,
novel modes of action and novel gene functions
have been uncovered [5,6]. Many antifungal drugs
target ergosterol [7] and transcriptome proﬁling had
pinpointed many novel ORFs with altered trans-
cription in response to such inhibitors. A compen-
dium of responses to different chemical challenges
was catalogued and was related to effects of speciﬁc
gene deletions. A compound with a previously
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response indicating sterol biosynthesis inhibition.
Speciﬁcally, sterol C8-isomerase was the target.
This protein and the related sigma receptors of
mammals are related in structure and inhibition of
C8-isomerase by neuroactive compounds, such as
emopamil, as has been observed before [9]. Eight
previously orphan ORFs were assigned a func-
tion in this study, including proteins required for
sterol metabolism, cell-wall function, mitochondrial
respiration and protein synthesis. For sterol bio-
synthesis an unsuspected function in sterol C4-
demethylation was revealed. This process requires
three activities, an oxygenase, a decarboxylase and
a keto-reductase, together with associated electron
donors, all of which were previously known genes.
The new protein Erg28p may function as a
molecular tether for this endoplasmic reticulum
associated complex. As sterol C4-demethylation is
a long-standing target for antifungal development,
this new information is important for designing new
strategies for drug discovery.
Concluding comments
We are entering the 21
st century, which will be an
era of pre-eminent importance for biology and post-
genomics. Yeast has, and will in the future, provide
an important platform for fundamental studies on
gene functions conserved in plants and man. The
genes required for viability in yeast, but absent in
man, are good potential targets for antifungals and
those essential in yeast and found in man are
important for understanding human health and
disease. The emergence of fungal infections as a
serious medical problem also stimulates the need for
such yeast studies in improving the rate of drug
development. The availability of a genome-wide set of
deletants as a resource to the wider scientiﬁc commu-
nity will lead to further stimulus in the use and value
of yeast studies. These will help in the context of big
and small science as the gene deletion strains will
make yeast studies more accessible to non-specialist
laboratories. Yeast studies have again led the way in
their approach in the post-genomic era.
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